| Article Access Statistics|
| Viewed||1941 |
| Printed||135 |
| Emailed||1 |
| PDF Downloaded||417 |
| Comments ||[Add] |
Click on image for details.
|Year : 2012 | Volume
| Issue : 2 | Page : 71-74
Low molecular weight heparin in prophylaxis of deep vein thrombosis in Asian general surgical patients: A Kashmir experience
Tanveer Iqbal Dar1, Khursheed Alam Wani1, Mohd Ashraf2, Aijaz Malik1, Sanjeed Ahmad3, Tariq A Gojwari3, Arshad Iqbal4
1 Department of General Surgery, SKIMS Soura, and SKIMS Medical College, Srinagar, J and K, India
2 Department of Pediatrics, SKIMS Soura, and SKIMS Medical College, Srinagar, J and K, India
3 Department of Radiodiagnosis, SKIMS Soura, and SKIMS Medical College, Srinagar, J and K, India
4 Department of Radiology, SKIMS Soura, and SKIMS Medical College, Srinagar, J and K, India
|Date of Web Publication||28-Jul-2012|
Tanveer Iqbal Dar
Senior Resident, Department of General Surgery, SKIMS, Srinagar, J and K
Background and Objectives: Deep vein thrombosis (DVT) occurs at a lower rate in Asia than in the rest of the world. We wanted to study the significance and efficacy of low molecular weight heparin (LMWH) in prophylaxis of DVT in major general surgical patients in the Kashmir Valley (India, Asia) so as to make it a routine in our patients. Patients and Methods: This was a prospective study in which the effect of LMWH was compared with no prophylaxis. Results: LMWHs are more effective than no prophylaxis in the prevention of DVT and pulmonary thromboembolism in highest-risk general surgical patients (odds ratio = 16.64; 95% confidence interval = 3.63-1130.03; P-value = 0.014). Conclusion: LMWHs have a significant prophylactic effect on DVT in general surgical patients, with a higher benefit to risk ratio, and, in spite of the low incidence of DVT in Asia, its prophylaxis should routinely be considered in this part of the world as well, preferably in the form of LMWHs.
Keywords: Heparin, prophylaxis, thrombosis
|How to cite this article:|
Dar TI, Wani KA, Ashraf M, Malik A, Ahmad S, Gojwari TA, Iqbal A. Low molecular weight heparin in prophylaxis of deep vein thrombosis in Asian general surgical patients: A Kashmir experience. Indian J Crit Care Med 2012;16:71-4
|How to cite this URL:|
Dar TI, Wani KA, Ashraf M, Malik A, Ahmad S, Gojwari TA, Iqbal A. Low molecular weight heparin in prophylaxis of deep vein thrombosis in Asian general surgical patients: A Kashmir experience. Indian J Crit Care Med [serial online] 2012 [cited 2014 Sep 21];16:71-4. Available from: http://www.ijccm.org/text.asp?2012/16/2/71/99107
| » Introduction|| |
Deep vein thrombosis (DVT) most commonly occurs in calf veins, and its most feared complication is pulmonary thrombo-embolism (PTE).  The incidence of DVT in the absence of prophylaxis is 16%,  25%  and 16-26% (in colorectal surgeries). , PTE following lower limb DVT is responsible for 10% of all hospital deaths.  The most common risk factors are major surgical procedures, especially hip replacement, and major abdominal surgeries.  Malignancy is known to cause DVT because of hyperfibrogenemia. , The most common symptom of DVT is pain in the calf  and the most significant sign is tenderness in the calf with ankle edema.  Duplex ultrasonography (USG) is the investigation of choice to diagnose DVT because it is a noninvasive and hazard-free method. 
Prevention of DVT should begin before the induction of anesthesia, as the thrombotic process begins intraoperatively and even before surgery in those with acute conditions.  Heparins have emerged as the agents of choice for DVT prophylaxis. Low molecular weight heparins (LMWHs) have replaced unfractionated heparin (UH) in many hospitals because of their many advantages  over the later, like they have superior or comparable efficacy and safety, they have very less risk of bleeding because of low immunogenicity, they have decreased frequency of thrombocytopenia  and osteopenia, they prevent early recurrence of thrombus in the treatment of DVT because they achieve higher quality of anticoagulation in the first hours,  they are taken as single daily dose and they do not require activated partial thromboplastin time monitoring.
| » Materials and Methods|| |
This was a prospective study conducted over 2.5 years from July 2005. A total of 215 highest-risk patients (as per risk score assigned to each risk factor by Caprini et al.)  undergoing elective and/or emergency general surgeries were recruited with informed written consent from the patients and approval from the hospital ethical committee. The main risk factors for DVT were documented [Table 1]. All the patients had normal preoperative femoral and popliteal veins on Doppler USG. Three patients were excluded because of low platelet count in two (<140 × 10 6 /L) and abnormal coagulogram in one. The patients were randomly grouped under prophylaxis group (n = 104) and control group without prophylaxis (n = 108). Open surgical procedure was performed on every patient. They were matched properly with respect to age, sex, disease type [Table 2], surgical procedure [Table 3] and other risk factors. Enoxaparin 0.4 mL (4000 IU) or nadroparin 0.3 mL (2850 IU) were administered subcutaneously in the anterior abdominal wall to all study group patients 1-2 h before induction of anesthesia and continued once a day till the 7 th postoperative day or discharge, whatever was earlier. All the patients were examined daily after surgery and duplex USG was performed on the 7 th postoperative day, or on appearance of signs of DVT, by blinded observers. Suspicious clinical findings were confirmed by duplex USG and PTE by ventilation/perfusion scan (v/q ratio). Established DVT was treated by UH in a dose of 80 U/kg intravenous stat followed by 18 U/kg infusion, along with warfarin 5 mg per day till therapeutic INR was achieved (2-2.5). After that, heparin was discontinued and warfarin continued for 6 months. The surgeon blinded to randomization assessed the intraoperative complications, postoperative platelets (PLT s) and blinded observers performed coagulogram on the 1 st , 3 rd , 5 th and 7 th postoperative days. Besides, the wound site was examined daily for bleeding and hematoma, and the injection site for pain and bruise. Data were prospectively analyzed by the use of SPSS 11.5 and Java two-way contingency table system, using Yates-corrected Chi square test with P-value <0.05 as significant.
| » Results|| |
The two groups were matched with respect to their age, sex and other known DVT risk factors [Table 1], diagnosis [Table 2] and surgical procedures [Table 3]. The mean age in years was 57.29 (9.617) years and 55.72 (10.672) years in study group and in the control group, respectively. DVT was significantly reduced by the use of LMWH. Eight of the 108 control group patients developed duplex USG-proven DVT, while none among the LMWH group did so (controls; DVT = 8/108, LMWH; DVT = 0/104, OR [odds ratio] = 16.64, P-value = 0.014). DVT was confirmed by duplex USG, and all the patients were symptomatic for DVT. Pain with ankle edema was the most common symptom (50%) and calf tenderness the most common sign (87.5%). Two of the eight DVT patients died (25%) because of PTE on the 3 rd postoperative day, which was documented by duplex USG and ventilation perfusion scan, whereas the remaining six patients responded well to the treatment. Six of the eight DVT patients were more than 60 years of age, while only two were younger than 60 years (OR = 3.4, P = 0.247). All the eight DVT patients were among the malignancy cases (malignancy 8/172, benign 0/40, OR = 3.90, P = 0.352).
The surgeon who was blinded to the randomization did not perceive more difficulty in the LMWH group as compared with controls during the surgery
[Table 4]. Six patients on LMWH and two in the control group developed minor wound-site hemorrhage in the form of small hematomas and minor ooze (P = 0.256); none required blood transfusions, withdrawal of the drug or re-operation.
No significant difference was seen in the type of LMWH used (enoxaparin n = 60, DVT = 0. Nadroparin n = 44, DVT = 0. P = 1.00). Finally, there was no significant difference in the postoperative hospital stay among the two groups (LMWH, mean = 11.7 [4.1] days. Controls, mean = 11.2 [4.0] days. P = 0.400).
| » Discussion|| |
As per our study, DVT in the Kashmir Valley (Jammu and Kashmir, India) occurs at an incidence equal to or greater than that in other parts of Asia, but lower than that in the rest of the world. , Our study included highest-risk patients only, and the incidence of DVT was found to be 7.40% without prophylaxis, as compared with 0% in the study group (controls 8/108; LMWH 0/104; OR = 16.64. P = 0.014). This shows that DVT (and PTE) was reduced to 0 by the use of LMWH. Other studies support our results, showing significant reduction of DVT in general surgical patients by the use of
LMWH. ,,,, Yik Hong et al.,  in a randomized controlled trial on Asian patients, found a statistically significant reduction of DVT by the use of enoxaparin as compared with no prophylaxis in high-risk general surgical patients (3% versus 0%. P = 0.045). Mismetti et al. in a metaanalysis showed that LMWHs in prophylactic doses provide a 72% reduction in the risk of DVT as compared with no treatment or placebo. Various studies have found LMWH to be effective as UH in the prevention of DVT, but in view of its more convenient way of administration and overall risk benefit ratio, they advocated that LMWHs might be preferred over UH for DVT prophylaxis. ,,
All the cases of DVT occurred in cancer patients (OR = 3.90, P = 0.352). Although not statistically significant, this shows that cancer patients had 3.90-times more risk of developing DVT than benign cases. Malignancy is an independent risk factor whereas benign diseases need one or more risk factors to increase the risk of DVT. [6,8] Six of the eight DVT patients were >60 years of age (OR = 3.4, P = 0.247), showing a higher likelihood of developing DVT after the age of 60 years , consistent with Gutt et al. and Caprini et al.,  who categorized patients more than 60 years of age in the high-risk group for DVT. An incidence of 17.6% (four in hemicollectomies, two in abdominoperineal resection/low anterior resection, total 6/34), was found in colorectal surgeries without prophylaxis, matching with that of Torgensen et al. and Jorgensen et al.,  who separately found an incidence of DVT equal to 16-26% among colorectal surgeries in the absence of any prophylaxis.
The low incidence of DVT in the Asian population has been shown by many studies; 0.27%,  4.70% and 3.0%,  than in the rest of the world. , The actual cause of the low DVT incidence in Asia is not known; however, the overall low platelet count of people in the Valley has been documented in our study (<150 X 10 3 /dL = 40%; 151-200 X 10 3 /dL = 40%; 201-350 X 10 3 /dL = 20%), and its possibility of contributing to the low incidence of DVT needs to be proven in the future. Color Doppler has been used in many studies for the diagnosis of DVT ,, because of its easy availability, cost-effectiveness and hazard-free and noninvasive nature. Pain was the most common symptom in our study (75%), consistent with others,  and the most common sign was calf tenderness (75%), followed by ankle edema (50%), consistent with Scurr.  Six of the 104 patients on LMWH (5.77%) and two of the 108 (1.85%) patients in the control group developed wound-site hemorrhage in the form of minor ooze and hematoma (P = 0.256); none required withdrawal of the drug, blood transfusion or re-operation. Kakkar  and Bergqvist et al. found the incidence of wound hematoma as 3.9% and 6.7%, respectively, with none of the patients requiring blood transfusion, re-operation or withdrawal of the drug. Kakker et al. also found that there was no significant difference between LMWH and UH in terms of incisional or total blood loss during surgery, postoperative drainage or wound hematoma formation.
No patient developed adverse reactions at the injection site in the form of pain, erythema, inflammation and hemorrhage/echymosis, consistent with the observations of Bergqvist et al. No patient developed significant (<140 X 10 3 /dL) thrombocytopenia in our study, as shown by Warkentin et al.,  who found an incidence of 0-9% with the use of enoxaparin.
| » Conclusion|| |
In spite of the low-DVT incidence in Asian patients, its prophylaxis should routinely be considered in high-risk general surgical patients in this part of the world because of the increased mortality from PTE. And, LMWHs in view of their significant effect, higher benefit to risk ratio and convenience of administration, should preferably be used for this purpose.
| » References|| |
|1.||Mark AC, Victor JD. Vascular diseases of the extremities. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison's Principles of Internal Medicine. 15 th ed. New York City, U.S.: McGraw Hill Companies Inc; 2001. p. 1434-40. |
|2.||Lee LH, Gu KQ, Heng D. Deep vein thrombosis is not rare in Asia- The Singapore general hospital experience. Ann Acad Med Singapore 2002;31:761-4. |
|3.||Gutt C, Oniu T, Wolkener F, Mehrabi A, Mistry S, Buchler M. Prophylaxis and treatment of DVT in general surgery. Am J Surg 2005;189:14-2. |
|4.||Torngren S, Reiger A. Prophylaxis of deep vein thrombosis in colorectal surgery. Dis Colon Rectum 1982;25:563-5. |
|5.||Wille JP, Kjaergaard J, Thorup J. Postoperative thromboembolic complications despite heparin prophylaxis in major abdominal surgery. Ann Chir Gynaecol 1985;74:130-3. |
|6.||John HS, Smith PD. Venous disorders. In: Russell RC, Williams NS, Bulstrode CJK, editors. Bailey and Love's Short Practice of Surgery 23 rd ed. U.K. Oxford University Press, Hodder Arnold ; 2000. p. 251-3. |
|7.||Bergqvist D, Lowe GD, Berstad A, Haas S, Hirsh J, Lassen MR, et al. Prevention of venous thrombosis after surgery: A review of enoxaparin. Br J Surg 1992;79:495-8. |
|8.||Thromboembolic risk factors (THRIFT) consensus group. Risk of and prophylaxis of venous thromboembolism in hospital patients. BMJ 1992;305:567-4. |
|9.||Bergqvist D. Time of onset of thromboembolism. In: D Bergqvist, editor. Postoperative Thromboembolism. Berlin, Heidelberg: Springer-Verlag; 1983. p. 32-3. |
|10.||Robert IH. Anticoagulant, fibrinolytic and antiplatelet therapy. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison's Principals of Internal Medicine. 15 th ed. New York City, U.S.: McGraw Hill Companies Inc; 2001. p. 758. |
|11.||Theodore E, Warkentin TE, Levine MN, Hirsh J, Peter H, Robin SR, et al. Heparin induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5. |
|12.||The DVTENOX Study group. Markers of haemostatic system activation in acute deep venous thrombosis-evolution during the first days of heparin treatment. Thromb Haemost 1993;70:909-14. |
|13.||Caprini JA, Arcelus JI, Reyna JJ. Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin Hematol 2001;38 (Supp, 5):12-9. |
|14.||Yik HH, Francis SC, Adrian L, Kong WE, Denis N, Meng-Keng T. Randomized controlled trial of LMWH versus no DVT prophylaxis for major colon and rectal surgery in Asian patients. Dis Colon Rectum 1999;42:196-203. |
|15.||ENOXACAN study group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery. Br J Surg 1997;84:1099-03. |
|16.||Bergqvist D, Matzsch T, Bumarx US, Frisell J, Guilbaud O, Hallbook T, et al. LMWH given the evening before surgery compared with conventional low dose heparin in prevention of thrombosis. Br J Surg 1988;75;888-91. |
|17.||Mismette P, Laporte S, Darmon JY, Buchmuller A, Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 2001; 88: 913-30 |
|18.||Michael JL, Marcia L, McGory. A systematic review of deep venous thrombosis prophylaxis in cancer patients: Implications for improving quality. Ann Surg Oncol 2007;14:929-36. |
|19.||Kakkar VV, Boeckl O, Boneu B, Bordenave L, Brehm OA, Brucke P, et al. Efficacy and safety of a Low Molecular Weight Heparin and Standard Unfractionated heparin for prophylaxis of postoperative Venous Thromboembolism: Europian multicentric trial. World J Surg 1997;21:2-9. |
|20.||Nurmohamed, Verhaeghe R, Haas S, Iriarte JA, Vogel G, Van RA, et al. A comparative trial of Enoxaparin versus standard heparin for the prophylaxis of postoperative DVT in general surgery. Am J Surg 1995;169:567-71. |
|21.||Tsakok FH. Thromboembolic diseases in women. Ann Acad Med Singapore 1974;3:399-403. |
|22.||Clagett GP, Anderson FA, Heit J, Levine MN. Prevention of venous thromboembolism. Chest 1995;108 (4Suppl):312-4. |
|23.||Gazzaniga GM, Angelini G, Pastorini G, Santoro E, Lucchini M, Dal PM. Enoxaparin in the prevention of DVT after major surgery: Multicentric study. The Italian study group. Int Surg 1993;78;271-5. |
|24.||Kakkar VV, Murray WJ. Thrombosis research unit. Efficacy and safety of LMWH (cy216) in preventing postoperative venous thrombo embolism: A co-operative study. Br J Surg 1985;72:786-9. |
[Table 1], [Table 2], [Table 3], [Table 4]